Clinical trials: Obesity, Overweight
Obese Children and Adolescents
Digital Wellness Nurse - FIT Families: Virtual Family Intervention for Adolescent Obesity
The purpose of the research is to evaluate the digital wellness nurse (DWN) app to find out if it is helpful in delivering the FIT Families intervention. The study is sponsored by the National Institutes of Health (NIH).
- Trial name
- DWN-FIT (NCT07087808)
- Testing
- Digital Wellness Nurse - FIT Families
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Machine and Human Interaction
Chronic Weight Management
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
APD356-A001-402 is a multicenter, double-blind, randomized, parallel-group pilot study of 12-week duration in overweight and obese adults.
- Trial name
- NCT01987427
- Testing
- lorcaserin + phentermine-HCl
- Where
- 13 sites in United States
- Volunteers
- 344 people
- Sponsor
- Eisai Inc.
Healthy Participants
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.
- Trial name
- NCT06942923
- Testing
- AZD4144
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Health Behavior
DEMETRA - ADVICE-002-2022
The purpose of this study is to evaluate the safety and performance of DTXO App in improving weight loss and weight-loss maintenance in obese patients exposed to an experimental non-pharmacological treatment program.
- Conditions
- Obesity, Health Behavior, Life Style, Dietary Habits
- Trial name
- NCT05394779
- Testing
- DTXO APP
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Advice Pharma Group srl
Psoriatic Arthritis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide…
- Trial name
- TOGETHER-PsA (NCT06588296)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 86 sites in United States, Puerto Rico
- Volunteers
- 279 people
- Sponsor
- Eli Lilly and Company
Obesity
Awareness, Care & Treatment In Obesity Management
ACTION France is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product.
- Trial name
- ACTION-France (NCT05690789)
- Testing
- No treatment given
- Where
- France
- Volunteers
- 1,688 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids
Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and…
- Conditions
- Obesity, Overweight, Dyslipidemia
- Trial name
- NCT00526682
- Testing
- Irvingia/cissus combo
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gateway Health Alliance
Overweight, Obesity
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease.
- Trial name
- SELECT (NCT03574597)
- Testing
- Semaglutide
- Where
- 833 sites in United States, Algeria and 40 more
- Volunteers
- 17,604 people
- Sponsor
- Novo Nordisk A/S
Overweight/ Obesity
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
This is a multicenter, double-blind, randomized, placebo-controlled study conducted in overweight or obese subjects. This study is divided into the first stage and the second stage.
- Trial name
- NCT04904913
- Testing
- IBI362
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
A Study to Assess S-309309 in Healthy and Obese Participants
The primary aim of the study is to assess the safety and tolerability of S-309309 after oral administration in healthy adult or obese but otherwise healthy adult participants.
- Trial name
- NCT05247970
- Testing
- S-309309, Midazolam
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity, Weight Loss
Obese Patients With or Without Comorbidities (RIO-North America)
To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
- Trial name
- NCT00029861
- Testing
- Rimonabant (SR141716)
- Where
- 51 sites in United States, Canada
- Volunteers
- 3,045 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
- Trial name
- NCT03235050
- Testing
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose
- Where
- 119 sites in United States, Bulgaria and 6 more
- Volunteers
- 834 people
- Sponsor
- AstraZeneca
Healthy Volunteer
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral…
- Trial name
- NCT01018823
- Testing
- Ertugliflozin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants
A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants
The main purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of AZD5004 administered as multiple oral doses in healthy participants and to compare the relative bioavailability of two oral tablet…
- Trial name
- NCT06555822
- Testing
- AZD5004
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight or Obesity, CKD
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).
- Conditions
- Overweight or Obesity, CKD, Type 2 Diabetes
- Trial name
- NCT05936151
- Testing
- Retatrutide
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Eli Lilly and Company
Obesity
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less…
- Trial name
- NCT07817875
- Testing
- Tirzepatide
- Where
- 82 sites in United States, Belgium and 8 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Obesity
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity.
- Trial name
- NCT06970405
- Testing
- Garetosmab
- Sponsor
- Regeneron Pharmaceuticals
Obesity
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.
- Trial name
- NCT07812597
- Testing
- zovaglutide Arm 1, zovaglutide Arm 2, semaglutide
- Where
- 16 sites in China
- Volunteers
- 210 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.